BGM

MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Retrieved on: 
Wednesday, March 27, 2024
Research, Diabetes, Growth, Caregiver, Partnership, Patient, Acquisition, BGM, Heart, Investindustrial, MTD, Health technology, Pharmaceutical industry

MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.

Key Points: 
  • MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
  • This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
  • MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
  • Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.

MTD acquires Ypsomed's pen needle and BGM businesses, strengthening its leading position in diabetes care

Retrieved on: 
Wednesday, March 27, 2024
Research, Diabetes, Growth, Caregiver, Partnership, Patient, Acquisition, BGM, Heart, Investindustrial, MTD, Health technology, Pharmaceutical industry

MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.

Key Points: 
  • MILAN, March 27, 2024 /PRNewswire/ -- MTD (Medical Technology and Devices), a leading provider of medical technology solutions for self-care and professional use worldwide, announces the acquisition Ypsomed's pen needle and blood glucose monitoring (BGM) businesses.
  • This strategic move solidifies MTD's position as a globally leading player in pen needle production and enhances its comprehensive solution portfolio for diabetes care.
  • MTD, the second largest manufacturer of pen needles globally, will incorporate in its operations the pen needle and BGMs portfolio from Ypsomed - a leading developer and manufacturer of injection and infusion systems for self-medication for 40 years.
  • Charles Bouaziz, CEO of MTD, expresses enthusiasm for the partnership with Ypsomed and the opportunities it brings.

Ragnarok Origin Reinvented Version Launching in North, Central, South America on February 28, 2024

Retrieved on: 
Monday, February 26, 2024
3D, IOS, GGV, Android, Gravity, BGM, Online shopping

Ragnarok Origin is reinvented with 3D engine and higher quality of graphic compared to previous version.

Key Points: 
  • Ragnarok Origin is reinvented with 3D engine and higher quality of graphic compared to previous version.
  • The game will be available not only for iOS and Android, but also for PC version.
  • GGV Said, “We are very pleased to be able to introduce this reinvented Ragnarok Origin in North, Central, South America, which is loved by users in many regions.
  • I hope you can participate in the launching event quickly and get rich benefits.”
    [Ragnarok Origin Discord Page_ North, Central, South America] https://discord.com/invite/roolna
    [Ragnarok Origin Facebook Page_ North, Central, South America] https://www.facebook.com/RagnarokOriginNA

Medicare Coverage Significantly Expanded for the Eversense E3 CGM System

Retrieved on: 
Monday, February 12, 2024
Software, Mobile, Wireless, Professional Services, Consumer Electronics, Apps, Applications, Medical Devices, Technology, Health Technology, Health Insurance, Insurance, Health, Diabetes, Blood glucose monitoring, MAC, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

Retrieved on: 
Monday, February 12, 2024
Blood glucose monitoring, MAC, Diabetes, CGM, Macs, Himawari (satellites), NGS, Practitioner, History, Patient, Policy, Insulin, LCD, Physician, BGM, Pharmaceutical industry

PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that Medicare has significantly expanded access to the Eversense E3 CGM System, the longest lasting CGM available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal only patients, by the first three Medicare Administrative Contractors (MACs).

Key Points: 
  • Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple insulin administrations per day.
  • Physicians, nurse practitioners and physician assistants who are interested in offering the Eversense E3 CGM System can sign up at https://www.ascensiadiabetes.com/eversense/become-a-provider/ .
  • Alternatively, contact 1-844-SENSE4U (1-844-736-7348) to learn more about the first and only long-term implantable CGM system.
  • Ascensia Diabetes Care, the maker of the CONTOUR® Blood Glucose Monitoring (BGM) System portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring (CGM) Systems, is a PHC Holdings Corporation (TSE: 6523) company.

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Retrieved on: 
Tuesday, February 6, 2024
Technology, Mobile, Wireless, Diabetes, Health, Human Resources, Apps, Applications, Other Health, Professional Services, Other Science, Medical Devices, Software, General Health, Hardware, Science, Partnership, Multimedia, Growth, Tandem Diabetes Care, CGM, BGM, PHC, Patient, Safety, Longevity, Thermo Fisher Scientific, University, Pharmaceutical industry

PHC Holdings Corporation (TSE:6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care , a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.

Key Points: 
  • PHC Holdings Corporation (TSE:6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care , a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.
  • Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics.
  • View the full release here: https://www.businesswire.com/news/home/20240206408169/en/
    Mr. Hansen will be responsible for the global commercialization and growth of the innovative Eversense CGM, currently available in the U.S. and select European markets.
  • The full year 2024 growth outlook will be provided in the second quarter 2024 following an assessment of the current commercial plan by the new President of CGM at Ascensia Diabetes Care.

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Retrieved on: 
Tuesday, February 6, 2024
Diabetes, Medical Devices, Health, Apps, Applications, Technology, Partnership, Growth, Tandem Diabetes Care, CGM, BGM, PHC, Patient, Longevity, Thermo Fisher Scientific, University, Pharmaceutical industry

PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.

Key Points: 
  • PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that diabetes industry veteran Brian Hansen has been appointed to the newly created role of President of CGM at Ascensia Diabetes Care, effective February 6, 2024.
  • Ascensia is the exclusive global distributor of the Eversense® E3 CGM system developed and manufactured by Senseonics.
  • Mr. Hansen will be responsible for the global commercialization and growth of the innovative Eversense CGM, currently available in the U.S. and select European markets.
  • The full year 2024 growth outlook will be provided in the second quarter 2024 following an assessment of the current commercial plan by the new President of CGM at Ascensia Diabetes Care.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Saturday, January 13, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Tuesday, January 9, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Retrieved on: 
Tuesday, December 19, 2023
Crimmitschau, Partnership, CRC, BGM, Physician, Colorectal cancer, Health, Disease, AVIA, Education, Cancer, Quality management, Patient, Pharmaceutical industry

Bantleon selected ColoAlert®, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program (BGM).

Key Points: 
  • Bantleon selected ColoAlert®, Mainz Biomed’s highly efficacious and easy-to-use screening test for CRC, for its corporate health program (BGM).
  • Via the Company’s BGM program, Bantleon offers ColoAlert® to its employees across all three sites in Germany – Ulm, Ulm-Nord and Crimmitschau.
  • Bantleon employees are able to register using Mainz Biomed’s online portal and have the ColoAlert® test mailed to them.
  • As part of its commitment to the BGM program, Mainz Biomed provides education to employees and physicians on CRC and recommendations for next steps.